Pharmafile Logo

OTC Awards

Lucid Group scoop a win and a high commendation at Communiqué 2020

Due to the COVID-19 pandemic, this year’s Communiqué awards was a virtual ceremony, celebrating some of the most inspiring work and people in medical communications.Lucid Group were delighted to come...

Lucid Group Communications Limited

AstraZeneca AZ

EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer

PARP inhibitor now available for rare, life-threatening disease

Onyx Health Tackles Diabetes with New Client

Onyx Health have continued to grow as an agency during the COVID-19 downturn, expanding their business into the South East of England by winning a new Surrey based client.

Onyx Health

- PMLiVE

Mesoblast expands compassionate use COVID-19 programme

Will now include children with multisystem inflammatory syndrome

- PMLiVE

OPEN Health scoops up Medical Affairs Agency Award at Communiqué 2020

Agency proves ongoing expertise in medical affairs at virtual awards

- PMLiVE

OPEN Health Medical Communications is awarded Medical Affairs Agency of The Year at the Communiqué Awards 2020

We are delighted to announce that OPEN Health Medical Communications was named Medical Affairs Agency of the Year at the virtual 2020 Communiqué Awards ceremony on 02 July 2020.

OPEN Health

- PMLiVE

Keep your audiences close

How getting up close and personal with target audiences can fuel creativity

- PMLiVE

McCann Health London bolsters creative leadership team

Guy Swimer and Kieran Delaney will lead the team

- PMLiVE

EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug

Antibody drug conjugate gained approval in US in December

- PMLiVE

Regeneron’s COVID-19 antibody cocktail enters phase 3 trial

Drug will be evaluated in preventative trial testing uninfected participants

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

- PMLiVE

Launch leaders’ blog part 1

To delay or not to delay the launch – ‘that is the question’ nowadays

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links